Synta Pharmaceuticals Corp (NASDAQ:SNTA)’s shares rose by 6.55% on Friday


Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, Synta Pharmaceuticals Corp (NASDAQ:SNTA) rose by 6.55 %. The shares opened at a price of $4.02, which touched the intraday high of $4.23 which was the closing price of the day. Around 2.04 million exchanged hands over the trading day and an average volume of 1.73 million shares were traded over a 30 day period. The 52-week low of Synta Pharmaceuticals Corp (NASDAQ:SNTA) shares is $3.70 and its 52-week high is $11.88. The company has a market capitalization of $292.12 million.                                        

About the company

Synta Pharmaceuticals Corp (NASDAQ:SNTA) was formed on March 2000. It is a bio-pharmaceutical company. It concentrates on the discovery, development & commercializing small-molecule drugs for the treatment of severe medical conditions of patients suffering from inflammatory diseases and cancer. As of 31 December, 2011, the company had 2 different drug-candidates in clinical-trials for the treatment of multiple kinds of cancer & numerous drug candidates in preclinical-stages of development. Synta Pharmaceuticals Corp (NASDAQ:SNTA)’s drug candidates are discovered & developed internally.

The company used the chemical-compound library & integrated-discovery engine. In the year that ended on 31st December 2011, Synta Pharmaceuticals Corp (NASDAQ:SNTA) initiated a Phase-2b/3 clinical-trial named GALAXY. This trail was for ganetespib as a mix with docetaxel in some non-small cell lung cancer (NSCLC). In the year 2011, apart from focusing on its ganetespib program, Synta Pharmaceuticals Corp (NASDAQ:SNTA) also focused on the elesclomol & calcium-release activated calcium-modulator programs.

 Oncology Programs

Synta Pharmaceuticals Corp (NASDAQ:SNTA) had 2 clinical-stage programs and 1preclinical-stage program in the field of oncology, as of 31st December 2011. The company’s oncology programs are ganetespib/ Hsp90 Inhibitor; elesclomolwhich is the Mitochondria-Targeting Agent & STA-9584. Ganetespib is the company’s synthetic, small-molecule-inhibitor of Hsp90. This is a chaperone-protein that is necessary to the function of some other proteins, like tyrosine kinases that drives the growth, proliferation & survival of different types of cancer.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.